encapsulated faecal microbiota filtrate

Phase 3

encapsulated faecal microbiota filtrate is one of 44 therapeutic programs targeting Ulcerative Colitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Ulcerative ColitisActive, not recruiting

Ulcerative ColitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

104 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Humira

Novartis

Phase 3

19 2

Stelara

Johnson & Johnson

Phase 3

11 3

Velsipity

Pfizer

Phase 3

10 4

Jyseleca

Gilead

Phase 3

6 5

Skyrizi

AbbVie

Phase 3

6 6

Tremfya

Johnson & Johnson

Phase 3

2 7

Mounjaro

Eli Lilly

Phase 3

1 8

Mesalazine

Ferring

Phase 3

17 9

Plaquenil

Jazz Pharmaceuticals

Phase 2

1 10

Jardiance

Boehringer Ingelheim

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Active, not recruiting

Ulcerative Colitis

NCT03843385

Clinical

Trials by Indication[1]

Ulcerative Colitis1 trial

Longterm Transfer of FRozen Encapsulated Multidonor Stool Filtrate or Encapsulated Multidonor Microbiome for Chronic Active Ulcerative COlitis

Active, not recruiting·AAndreas Stallmach·Phase 3·NCT03843385·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for encapsulated faecal microbiota filtrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for encapsulated faecal microbiota filtrate. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Andreas Stallmach company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: AAndreas Stallmach

encapsulated faecal microbiota filtrate

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Ulcerative Colitis1 trial

References

Drug Info

Quick Facts

Related News